Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Provided By GlobeNewswire
Last update: Dec 7, 2024
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025
Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025
Read more at globenewswire.com
